N-Benzoyl-N’-phenylthiourea derivatives and macrophage migration inhibitory factor

Excerpt:


J. Pharm. Pharmacogn. Res., vol. 11, no. 5, pp. 902-925, Sep-Oct 2023. DOI: https://doi.org/10.56499/jppres23.1657_11.5.902 Original Article Synthesis and in vitro activity tests of N-benzoyl-N'-phenylthiourea derivatives as macrophage migration inhibitory factor [Síntesis y pruebas de actividad in vitro de derivados de N-benzoil-N'-feniltiourea como factor inhibidor de la migración de macrófagos] Dini Kesuma1, Galih S. Putra2*, Tegar A. … Continue reading N-Benzoyl-N’-phenylthiourea derivatives and macrophage migration inhibitory factor

J. Pharm. Pharmacogn. Res., vol. 11, no. 5, pp. 902-925, Sep-Oct 2023.

DOI: https://doi.org/10.56499/jppres23.1657_11.5.902

Original Article

Synthesis and in vitro activity tests of N-benzoyl-N'-phenylthiourea derivatives as macrophage migration inhibitory factor

[Síntesis y pruebas de actividad in vitro de derivados de N-benzoil-N'-feniltiourea como factor inhibidor de la migración de macrófagos]

Dini Kesuma1, Galih S. Putra2*, Tegar A. Yuniarta1,Farida Suhud1, I G.A. Sumartha1, Sawitri Boengas3, Melanny I. Sulistyowaty4, Tjie Kok5

1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Surabaya, Surabaya, Indonesia.

2Department of Chemistry, Faculty of Mathematics and Natural Sciences, State University of Malang, Malang Indonesia.

3Faculty of Medicine, University of Surabaya, Surabaya, Indonesia.

4Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia.

5 Faculty of Biotechnology, University of Surabaya, Surabaya, Indonesia.

*E-mail: galih.satrio.fmipa@um.ac.id

Abstract

Context: The COVID-19 pandemic in 2020 resulted in widespread mortalities due to cytokine storms in the affected patients. Macrophage migration inhibitory factor (MIF) is one of the most interesting targets in developing anti-COVID-19 drugs. Some thiourea compounds have been identified as having potential as MIF inhibitors.

Aims: To investigate MIF inhibitory activity of N-benzoyl-N'-phenylthiourea derivatives.

Methods: The study consists of in-silico activity prediction of designed compounds using a molecular docking approach against MIF protein (PDB ID: 1LJT). Afterwards, the designed compounds were synthesized and tested in vitro using the tautomerase activity approach.

Results: The molecular docking study showed that all designed compounds possess comparable docking scores to the native ligand of the protein. MIF Assay performed on compounds (1) and (2) indicated a decrease in tautomerase activity of the MIF target protein of only 10.1 and 6.2%, respectively, compared to the positive control.

Conclusions: In silico results predicted better bioactivity against MIF protein, but the result does not translate to the in vitro assay, where two of the designed compounds possess only low inhibitory activity.

Keywords: 1LJT; MIF assay; tautomerase activity; thiourea derivatives.

jppres_pdf_free

Resumen

Contexto: La pandemia de COVID-19 en 2020 provocó mortalidades generalizadas debido a las tormentas de citocinas en los pacientes afectados. El factor inhibidor de la migración de macrófagos (MIF) es una de las dianas más interesantes en el desarrollo de fármacos anti-COVID-19. Se han identificado algunos compuestos de tiourea con potencial como inhibidores de MIF.

Objetivos: Investigar la actividad inhibidora de MIF de derivados de N-benzoil-N'-feniltiourea.

Métodos: El estudio consiste en la predicción in silico de la actividad de los compuestos diseñados utilizando un enfoque de acoplamiento molecular frente a la proteína MIF (PDB ID: 1LJT). Posteriormente, los compuestos diseñados se sintetizaron y probaron in vitro mediante el método de actividad tautomerasa.

Resultados: El estudio de acoplamiento molecular mostró que todos los compuestos diseñados poseen puntuaciones de acoplamiento comparables al ligando nativo de la proteína. El ensayo MIF realizado con los compuestos (1) y (2) indicó una disminución de la actividad tautomerasa de la proteína diana MIF de sólo el 10,1 y el 6,2%, respectivamente, en comparación con el control positivo.

Conclusiones: Los resultados in silico predijeron una mejor bioactividad frente a la proteína MIF, pero el resultado no se traslada al ensayo in vitro, donde dos de los compuestos diseñados sólo poseen una baja actividad inhibitoria.

Palabras Clave: actividad tautomerasa; derivados tiourea; ensayo MIF; 1LJT.

jppres_pdf_free
Citation Format: Kesuma D, Putra GS, Yuniarta TA, Suhud F, Sumartha IGA, Boengas S, Sulistyowati MI, Kok T (2023) Synthesis and in vitro activity tests of N-benzoyl-N'-phenylthiourea derivatives as macrophage migration inhibitory factor. J Pharm Pharmacogn Res 11(5): 902–925. https://doi.org/10.56499/jppres23.1657_11.5.902
References

Aslan A, Aslan C, Zolbanin NM, Jafari R (2021) Acute respiratory distress syndrome in COVID-19: Possible mechanisms and therapeutic management. Pneumonia. 13: 14. https://doi.org/10.1186/s41479-021-00092-9

Bleilevens C, Soppert J, Hoffmann A, Breuer T, Bernhagen J, Martin L, Stiehler L, Marx G, Dreher M, Stoppe C, Simon TP (2021) Macrophage migration inhibitory factor (MIF) plasma concentration in critically ill COVID-19 patients: A prospective observational study. Diagnostics (Basel) 11(2): 332. https://doi.org/10.3390/diagnostics11020332

Donnelly S, Haslett C, Reid PT, Grant IS, Wallace WAH, Metz CN, Bruce LJ, Bucala R (1997) Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 3: 320–323. https://doi.org/10.1038/nm0397-320

Gao L, Flores C, Fan-Ma S, Miller EJ, Moitra J, Moreno L, Wadgaonkar R, Simon B, Brower R, Sevransky J, Tuder RM, Maloney JP, Moss M, Shanholtz C, Yates CR, Meduri GU, Ye SQ, Barnes KC, Garcia JG (2007) Macrophage migration inhibitory factor in acute lung injury: Expression, biomarker, and associations. Transl Res 150(1): 18–29. https://doi.org/10.1016/j.trsl.2007.02.007

Kesuma D, Kirtishanti A, Makayasa CHA, Sumartha IGA (2023) Anticancer activity of N-(4-t-butylbenzoyl)-N’-phenylthiourea: Molecular docking, synthesis, and cytotoxic activity in breast and cervical cancer cells. J Pharm Pharmacogn Res 11(2): 208–215. https://doi.org/10.56499/jppres22.1508_11.2.208

 Kesuma D, Putra GS, Yuniarta TA.(2022a). Synthesis and cytotoxic activity of N-(2,4-dichloro)benzoyl-N’- phenylthiourea against human breast cancer cell line. Thai J Pharm Sci 46(2): 173–176.

Kesuma D, Siswandono, Purwanto BT, Rudyanto M (2020) Synthesis and anticancer evaluation of N-benzoyl-N'-phenyltiourea derivatives against human breast cancer cells (T47D). J Chin Pharm Sci 29(2): 123–129. https://doi.org/10.5246/jcps.2020.02.010

Kesuma D, Siswandono, Kirtishanti A (2022b) Molecular docking and biological activity of n-(4-methoxy)-benzoyl-n’-phenylthiourea and n-(4-trifluoro)-benzoyl-n’-phenylthiourea as anti-breast cancer candidates. Rasayan J Chem 15(2): 1503–1508. https://doi.org/10.31788/RJC.2022.1526836

Kesuma D, Makayasa CHA, Suhud F, Azminah A, Yuniarta TA, Sumartha I, Risthanti RR, Dani FF (2022c) Structure modification: Effect of lipophilic, electronic, and steric parameters of n-benzoyl-n'-phenylthiourea compounds on antiviral activity of COVID-19 by in silico. Rasayan J Chem 15(2): 1445–1449. http://doi.org/10.31788/RJC.2022.1526809

Kok T, Wasiel AA, Dekker FJ, Poelarends GJ, Cool RH (2018) High yield production of human invariant chain CD74 constructs fused to solubility-enhancing peptides and characterization of their MIF-binding capacities. Protein Expr Purif 148: 46–53. http://doi.org/10.1016/j.pep.2018.03.008

Kruger NJ (2002) The Bradford Method for Protein Quantitation. In: Walker JM (eds). The Protein Protocols Handbook. Springer Protocols Handbooks. Humana Press, pp. 15–22. http://doi.org/10.1385/1-59259-169-8:15

Lubetsky JB, Dios A, Han J, Aljabari B, Ruzsicska B, Mitchell R, Lolis E, Al-Abed Y (2002) The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 277(28): 24976–24982. http://doi.org/10.1074/jbc.M203220200

NIH (2021) COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/

Putra GS, Widiyana AP, Muchlashi LA, Sulistyowati MI, Ekowati J, Budiati T (2017) The influence of ratio pyridine and triethylamine catalysts on synthesis 2-phenyl-benzo [D][1, 3] oxazine-4-on derivatives. J Chem Pharm Res 8(1): 73–80.

Turk FE, Fauvet B, Sakouhi HO, Lugari A, Betzi S, Roche P, Morelli X, Lashuel HA (2010) An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg Med Chem 18: 5425–5440. https://doi.org/10.1016/j.bmc.2010.05.010

WHO (2020). Corticosteroids for COVID-19: Living guidance, 2 September 2020

Xiao Z, Fokkens M, Chen D, Kok T, Proietti G, Merkerk RV, Poelarends GJ, Dekker FJ (2020) Structure-activity relationships for binding of 4-substituted triazole-phenols to macrophage migration inhibitory factor (MIF). Eur J Med Chem 186: 1118492. https://doi.org/10.1016/j.ejmech.2019.111849

© 2023 Journal of Pharmacy & Pharmacognosy Research

Anti-dormant mycobacterial of marine-derived fungi
J. Pharm. Pharmacogn. Res., vol. 13, no. 1, pp. 16-26, Jan-Feb 2025. DOI: https://doi.org/10.56499/jppres24.1953_13.1.16 Original Article Activity of ethyl acetate extracts of marine-derived fungi against active and hypoxia-induced dormant Mycobacterium [Actividad de extractos de acetato de etilo de hongos de origen marino contra Mycobacterium latente activa e inducida por hipoxia] Muhammad Azhari1, Atik Pereztia Litanjuasari1, … Continue reading Anti-dormant mycobacterial of marine-derived fungi
Rift Valley fever virus RdRp inhibition by RNA polymerase inhibitors
J. Pharm. Pharmacogn. Res., vol. 13, no. 1, pp. 1-15, Jan-Feb 2025. DOI: https://doi.org/10.56499/jppres24.1967_13.1.1 Original Article In silico study of RNA polymerase inhibitor drugs for Rift Valley fever virus using RdRp protein as the target [Estudio in silico de fármacos inhibidores de la ARN polimerasa para el virus de la fiebre del valle del Rift … Continue reading Rift Valley fever virus RdRp inhibition by RNA polymerase inhibitors
Probable interaction between levothyroxine and Thymus vulgaris
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1196-1198, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.2008_12.6.1196 Case Report Probable interaction between levothyroxine sodium and thyme (Thymus vulgaris), about a case report [Interacción probable entre levotiroxina sódica y tomillo (Thymus vulgaris), sobre un reporte de caso] Nassima Elyebdri1,2*, Sihem Baba Ahmed1, Nessrine Abourejal1, Lotfi Loudjedi3, Assia Bououden3, Nour … Continue reading Probable interaction between levothyroxine and Thymus vulgaris

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio